Y-mabs therapeutics, inc. announces positive omburtamab clinical data

Y-mabs therapeutics, inc. announced a clinical update on omburtamab for the treatment of central nervous system (cns) leptomeningeal metastases from neuroblastoma and a number of additional cancer indications. data was presented at the international society of pediatric oncology (siop) annual congress in lyon, france on october 26, 2019 by dr. kim kramer from memorial sloan kettering cancer center (msk) in new york. an updated data readout as of june 30, 2019 from a single-center study at msk (study 03-133), where patients with cns/leptomeningeal metastases from neuroblastoma received up to two doses of radiolabelled omburtamab, showed that for the 107 evaluable patients, the median survival had increased to 50.8 months, with the final median not yet being reached. this compared well to a median survival of 47.1 months at the prior data readout based on the first 93 patients in the study. in addition, 68 patients diagnosed with other cns cancers, including metastatic tumors had received a total of 201 injections of omburtamab. injections were routinely administered in an outpatient setting. rare self-limited adverse events included grade 1 or 2 fever, headache, vomiting; 3 injections were associated with grade 3 toxicities requiring discontinuation of therapy including chemical meningitis and increasing communicating hydrocephalus. although not a dose limiting toxicity, myelosuppression occurred in patients who had received craniospinal radiation and at dose levels exceeding 60mci. the primary cns diagnoses included medulloblastoma (n=27), ependymoma (n=9), and embryonal tumors with multilayered rosettes (n=4), while metastatic tumors included sarcoma (n=9), melanoma (n=5), and other tumors (n=14). as of now, 26 of the 68 patients with these highly lethal diagnoses remain alive.
YMAB Ratings Summary
YMAB Quant Ranking